Stock Research Monitor: IQV, LH, and OPGN
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. For today, WallStEquities.com monitors four Medical Laboratories and Research companies, particularly, IQVIA Holdings Inc. (NYSE: IQV), Laboratory Corp. of America Holdings (NYSE: LH), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). Medical laboratories are independent, commercial enterprises that provide information to the healthcare professionals about the severity, onset, and reason of patients’ physical ailments. All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
IQVIA Holdings
Durham, North Carolina headquartered IQVIA Holdings Inc.’s stock finished Wednesday’s session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company’s shares have advanced 4.93% and 2.19%, respectively. Additionally, the stock has gained 17.52% over the past year. Shares of the Company are trading above their 50-day and 200-day moving averages by 1.49% and 0.82%, respectively. Moreover, shares of IQVIA, which provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and Asia/Pacific, have a Relative Strength Index (RSI) of 53.00.
On May 17th, 2018, IQVIA announced that in light of recent market conditions, the Company and the selling stockholders will not proceed with the previously announced secondary public offering and concurrent repurchase of common stock. Get the full research report on IQV for free by clicking below at:
www.wallstequities.com/registration/?symbol=IQV
Laboratory Corp. of America Holdings
Shares in Burlington, North Carolina headquartered Laboratory Corp. of America Holdings rose 1.65%, ending yesterday’s session at $183.08. A total volume of 728,169 shares was traded, which was above their three months average volume of 724,210 shares. The stock has gained 7.22% in the past month, 6.01% in the previous three months, and 32.17% over the past year. The Company’s shares are trading 7.97% above their 50-day moving average and 12.58% above their 200-day moving average. Moreover, shares of the Company, which operates as an independent clinical laboratory company worldwide, have an RSI of 70.12.
On May 01st, 2018, research firm Robert W. Baird upgraded the Company’s stock rating from ‘Neutral’ to ‘Outperform’.
On May 25th, 2018, LabCorp and Aetna extended and expanded their existing agreement, making the former a preferred national laboratory for substantially all of Aetna’s members, beginning January 01st, 2019. The expanded agreement will provide more than 20 million eligible members with in-network access to LabCorp’s full range of laboratory services. Find your free research report on LH at:
www.wallstequities.com/registration/?symbol=LH
OpGen
On Wednesday, Gaithersburg, Maryland headquartered OpGen Inc.’s stock dropped 4.46%, to close the day at $2.14. A total volume of 406,479 shares was traded. The Company’s shares have advanced 15.05% in the last month. The stock is trading 12.62% above its 50-day moving average. Additionally, shares of OpGen, which engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide, have an RSI of 62.15.
On May 08th, 2018, OpGen reported its results for the three months ended March 31st, 2018. Total revenue for Q1 2018 was $0.85 million, operating expenses were $3.9 million, and net loss available to common stockholders was $3.0 million. Cash and cash equivalents were $10.3 million, as of March 31st, 2018. Sign up today for the free research report on OPGN at:
www.wallstequities.com/registration/?symbol=OPGN
Organovo Holdings
Shares in San Diego, California headquartered Organovo Holdings Inc. ended the day 5.46% higher at $1.93. A total volume of 1.02 million shares was traded. The stock has surged 55.95% in the last month and 91.09% in the previous three months. The Company’s shares are trading above their 50-day and 200-day moving averages by 53.27% and 29.68%, respectively. Furthermore, shares of Organovo, which designs and creates functional and 3D human tissues for use in medical research and therapeutic applications, have an RSI of 71.17.
On May 03rd, 2018, Organovo announced that it has joined a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (“ARMI”). Headquartered in Manchester, New Hampshire, ARMI is the 12th Manufacturing USA Institute. Wall St. Equities’ research coverage also includes the downloadable free report on ONVO at:
www.wallstequities.com/registration/?symbol=ONVO
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities
ReleaseID: 501362
